Our investors
A syndicate that knows this disease
Islex raised a $30M Series A to advance ILX-101 through IND-enabling work and into initial clinical studies. Our investors bring life-science company building and deep specialization in type 1 diabetes.
Series A
Who backed us
Replace each block below with the investor’s logo image once you have approved marks on file.
Investor descriptions intentionally omitted. [CLIENT INPUT REQUIRED — confirm approved one-line descriptors and logo usage rights with each firm before publishing.]
Use of proceeds
What the Series A is funding
The round is intended to carry ILX-101 from development candidate through IND-enabling work and into a proof-of-principle study in type 1 diabetes, while establishing feasibility for the conjugate pipeline.
ILX-101 development
- IND-enabling nonclinical and toxicology work
- CMC development through GMP supply
- Regulatory path to IND and clinical trial authorization
- First-in-human safety and dose-finding, followed by a proof-of-principle study in type 1 diabetes
Conjugate feasibility
- Target biology and feasibility for antibody–drug conjugates
- Proof-of-concept across candidate payload classes
- Selection of a development candidate for the conjugate program
- Translational biomarker and mechanistic studies
Development timelines and study plans are subject to regulatory alignment and may change.
Scientific advisory board
Who we take advice from
Our advisors span ZnT8 biology, clinical endocrinology, islet transplantation and immune-disease trial design.
- Dr. Dax FuFounder. ZnT8 expert and lead author.
- Dr. Jason GagliaDirector, Joslin Diabetes Center.
- Dr. Aaron MichelsBarbara Davis Center for Diabetes.
- Dr. Maria GolsonAssistant Professor of Endocrinology, Johns Hopkins University.
- Dr. George HarbStem-cell derived islet biologist.
- Dr. Keith KauffmanIndustry endocrinologist, 33 years, formerly Merck.
- Dr. Cate SpeakeClinical studies expert in immune disease.
[VERIFY — “Barbara Center for Diabetes” in source materials is rendered here as the Barbara Davis Center for Diabetes. Confirm with Dr. Michels before publishing.]
Investor and partnering inquiries
For questions about the company, the program or potential collaboration, reach us directly.
ILX-101 and ILX-101-plus are investigational and have not been approved by the U.S. Food and Drug Administration or any other regulatory authority. Their safety and efficacy have not been established. Findings described on this site are from preclinical research and are not predictive of results in humans. Nothing on this page is an offer to sell or a solicitation of an offer to buy any security.